

04.28.06

Attorney Docket No. 55600-8014.US03

IFN



Express Mail Label EV 337 220 008 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Liu, et al.

APPLICATION No.: 10/825,068

FILED: April 14, 2004

FOR: **METHOD OF TREATMENT USING
INTERFERON-TAU**

EXAMINER: Unassigned

ART UNIT: 1764

CONF. NO: 7994

**Supplemental Information Disclosure Statement Within Three Months of
Application Filing or Before First Action – 37 C.F.R. § 1.97(b)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last (37 C.F.R. § 1.97(b)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

Copies of references numbered 33, 39, 40, 48, and 53 can be found in parent U.S. Application No. 10/824,710. References numbered 30-31, 34, 37, 45-46, and 51 can be found in U.S. parent Application No. 10/884,741. References numbered 32, 35, 36, 38, 41, 42, 47, 50, 52, 55 and 56 can be found in U.S. parent Application No. 11/112,369. References numbered 43 and 49 were cited by the Examiner in U.S. parent Application No. 10/824,710.

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,
Perkins Coie LLP

Date: 4/26/06

Judy M. Mohr
Judy M. Mohr
Registration No. 38,563

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

O I P E
APR 26 2006
P R I M A R Y P A T E N T
SHEET 1 OF 3
Form PTO-1449 (Modified)
Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	10/825,068
Confirmation Number	7994
Filing Date	April 14, 2004
First Named Inventor	Chih-Ping Liu
1764	1645
Examiner Name	Unassigned
Attorney Docket No.	55600-8014.US03

1

of

3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	1	H22		Creasey, et al.	02/04/86	
	2	4,683,195		Mullis, et al.	07/28/87	
	3	4,683,202		Mullis	07/28/87	
	4	4,752,479		Briggs, et al.	06/21/88	
	5	4,766,068		Oeda, et al.	08/23/88	
	6	4,769,235		Schlesinger, et al.	09/06/88	
	7	5,098,702		Zimmerman, et al.	03/24/92	
	8	5,128,126		Boniver	07/07/92	
	9	5,368,854		Rennick	11/29/94	
	10	5,376,368		Ulich	12/27/94	
	11	5,425,940		Zimmerman, et al.	06/20/95	
	12	5,563,126		Allen, et al.	10/08/96	
	13	5,632,983		Hadden	05/27/97	
	14	5,880,114		Deluca, et al.	03/09/99	
	15	5,942,223		Bazer, et al.	08/24/99	
	16	6,080,742		Germann, et al.	06/27/00	
	17	6,346,243	B1	Brod	02/12/02	
	18	2003/0017136	A1	Cruz, et al.	01/23/03	
	19	2003/0055013	A1	Brass	03/20/03	
	20	2003/0086901	A1	Cruz, et al.	05/08/03	
	21	6,613,354	B2	Depui, et al.	09/02/03	
	22	2003/0185799	A1	Rudolph	10/02/03	
	23	2003/0229044	A1	Steinman, et al.	12/11/03	
	24	2003/0232033	A1	Cantrell	12/18/03	
	25	2004/0009896	A1	Glynn, et al.	01/15/04	
	26	2004/0013695	A1	Vande-Velde	01/22/04	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/825,068
				Confirmation Number	7994
				Filing Date	April 14, 2004
				First Named Inventor	Chih-Ping Liu
				1764	1645
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket No.	55600-8014.US03

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	27	6,699,496	B1	Kojima, <i>et al.</i>	03/02/04	
	28	2004/0086508	A1	Skurkovich, <i>et al.</i>	05/06/04	
	29	2005/0014734	A1	Chang	01/20/05	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document
		Office	NUMBER	Kind Code (if known)		
	30	EP	0 814 831	B1	Soos, <i>et al.</i>	06/19/02
	31	EP	1 241 242	A2	Paeschke, <i>et al.</i>	09/18/02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.				
	32	Asadullah, K., <i>et al.</i> , <i>Pharmacological Reviews</i> <u>55</u> (2):241-269, (2003).				
	33	Chaouat, G., <i>et al.</i> , <i>J Immunology</i> <u>154</u> (9):4261-4268, (1995).				
	34	Elices, M.J., <i>Current Opinion in Investigational Drugs</i> <u>4</u> (11):1354-1362, (2003).				
	35	Fainardi, E., <i>et al.</i> , <i>J of Neuroimmunology</i> <u>142</u> :149-158, (2003).				
	36	Goldman, M. and Velu, T., <i>Advances in Nephrology</i> <u>24</u> :79-90, (1995).				
	37	Groetzner, J., <i>et al.</i> , <i>Transplantation</i> <u>77</u> (4):568-574, (2004).				
	38	Jacobs, R., <i>et al.</i> , <i>Rheumatology</i> <u>40</u> :868-875, (2001).				
	39	Kappos, L., <i>et al.</i> , <i>J Neurol</i> , <u>251</u> (Suppl 5):V/57-V/64, (2004).				
	40	Killestein, J. and Polman, C.H., <i>Curr Opin Neurol</i> , <u>18</u> :253-260, (2005).				
	41	Kozlowski, L., <i>et al.</i> , <i>Annales Acedemiae Medicae Bialostocensis</i> <u>48</u> :82-84, (2003).				

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/825,068
				Confirmation Number	7994
				Filing Date	April 14, 2004
				First Named Inventor	Chih-Ping Liu
				1764	1645
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket No.	55600-8014.US03

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.
	42	Leon, L.R., <i>et al.</i> , <i>Annals of the New York Academy of Sciences</i> <u>856</u> :69-75, (1998).
	43	Li, M.C. and He, S.H., <i>World Journal of Gastroenterology</i> <u>10</u> (5):620-625, (2004).
	44	Macdougall, I.C. and Cooper, A.C., <i>Nephrol Dial Transplant</i> <u>17</u> (Supp 11):39-43, (2002).
	45	Martin, J., <i>et al.</i> , <i>Cytokine</i> <u>10</u> (8):635-644, (1998).
	46	Miller, D.H., <i>et al.</i> , <i>N Engl J Med</i> <u>348</u> :15-23, (2003).
	47	Murray, H.W., <i>et al.</i> , <i>Infection and Immunity</i> <u>70</u> (11):6284-6293, (2002).
	48	Olek, M.J., <i>et al.</i> , <i>Neurology</i> <u>56</u> (Suppl 3):A76, (2001).
	49	van Roon, J., <i>et al.</i> , <i>Journal of Rheumatology</i> <u>30</u> :648-651, abstract only.
	50	Rennick, D.M. and Fort, M.M., <i>Am J Physiol Gastrointest Liver Physiol</i> <u>278</u> :G829-G833, (2000).
	51	Sandborn, W.J. and Yednock, T.A., <i>American Journal of Gastroenterology</i> <u>98</u> (11):2372-2382, (2003).
	52	Soltys, J., <i>et al.</i> , <i>The Journal of Immunology</i> <u>168</u> :1903-1910, (2002).
	53	Tuo, W., <i>et al.</i> , <i>J Interferon and Cytokine Research</i> <u>19</u> (2):179-187, (1999).
	54	Vanderhoff, B.T., and Tahboub, R.M., <i>Am Fam Physician</i> <u>66</u> :273-280, (2002).
	55	Wang, B., <i>et al.</i> , <i>J Immunol</i> <u>162</u> :277-283, (1999).
	56	Waubant, E., <i>et al.</i> , <i>J of Neuroimmunology</i> <u>112</u> :139-145, (2001).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	